At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 287 enrolled
Drug / intervention
Ergoferon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
International Multicenter Double-blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children
In Brief
A Phase 4 clinical trial evaluating Ergoferon and Placebo for Acute Respiratory Viral Infections. Completed, enrolled 287 participants across 13 sites in 2 countries.
Detailed Summary
The international multicenter double-blind placebo-controlled randomized clinical study in parallel groups.The objective of this study is to obtain additional data on the efficacy and safety of Ergoferon in the treatment of acute respiratory viral infections (ARVI) in children aged from 6 months to 6 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Respiratory Viral Infections
CountriesKazakhstan, Russia
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedFeb 2017
Primary CompletionJan 2019
TodayJul 2026
First PostedFeb 1, 2017
Enrollment StartOct 7, 2016
Primary CompletionJan 9, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.4 years ago
Interventions
Ergoferondrug
For oral use.
Placebodrug
For oral use.